Zevra Therapeutics, Inc. (ZVRA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ZVRA Revenue Growth
Revenue Breakdown (FY 2023)
ZVRA's revenue distribution by segment and geography for fiscal year 2023
By Product/Segment
ZVRA Revenue Analysis (2014–2025)
As of May 8, 2026, Zevra Therapeutics, Inc. (ZVRA) generated trailing twelve-month (TTM) revenue of $122.3 million, reflecting explosive growth of +77.5% year-over-year. The most recent quarter (Q1 2026) recorded $36.2 million in revenue, up 6.1% sequentially.
Looking at the longer-term picture, ZVRA's 5-year compound annual growth rate (CAGR) stands at +51.6%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $106.5 million in 2025, representing a new all-time high.
Revenue diversification analysis shows ZVRA's business is primarily driven by License (100%). With over half of revenue concentrated in License, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including RARE (+13.3% YoY), FOLD (+20.0% YoY), and ACAD (+9.9% YoY), ZVRA has outperformed the peer group in terms of revenue growth. Compare ZVRA vs RARE →
ZVRA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ZVRACurrent | $122M | +77.5% | +51.6% | -4.0% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 FOLD | $634M | +20.0% | +19.4% | 5.4% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% | |
 PTCT | $1.7B | -53.3% | +35.4% | 49.5% | |
 KRYS | $389M | +25.1% | - | 41.5% |
ZVRA Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $106.5M | +350.9% | $90.0M | 84.5% | $-4,233,000 | -4.0% |
| 2024 | $23.6M | -14.0% | $16.2M | 68.6% | $-87,003,000 | -368.5% |
| 2023 | $27.5M | +170.3% | $24.5M | 89.3% | $-49,604,000 | -180.6% |
| 2022 | $10.2M | -64.5% | $9.9M | 97.8% | $-42,565,000 | -418.9% |
| 2021 | $28.6M | +115.6% | $26.6M | 92.8% | $7.7M | 27.0% |
| 2020 | $13.3M | +3.5% | $12.0M | 90.2% | $-5,609,000 | -42.2% |
| 2019 | $12.8M | - | $9.9M | 77.1% | $-20,337,000 | -158.4% |
| 2018 | $0 | - | $-324,000 | - | $-55,903,000 | - |
| 2017 | $0 | - | $-336,000 | - | $-33,366,000 | - |
| 2016 | $0 | - | $-175,000 | - | $-37,482,000 | - |
See ZVRA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ZVRA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ZVRA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonZVRA — Frequently Asked Questions
Quick answers to the most common questions about buying ZVRA stock.
Is ZVRA's revenue growth accelerating or slowing?
ZVRA revenue is accelerating at +77.5% year-over-year, exceeding the 5-year CAGR of +51.6%. TTM revenue reached $122M. Growth momentum has increased versus prior periods.
What is ZVRA's long-term revenue growth rate?
Zevra Therapeutics, Inc.'s 5-year revenue CAGR of +51.6% reflects the sustained expansion pattern. Current YoY growth of +77.5% is above this long-term average.
How is ZVRA's revenue distributed by segment?
ZVRA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.